Efficacy of treatments for <i>β</i>-coronaviruses associated respiratory diseases: a systematic review_Chinese Journal of Evidence-Based Medicine

Authors：

ZENG Xueyang ¹ , ZHOU Qingxin ¹ , ZHANG Jingxue ¹ , YANG Zhirong ² , CAI Xianming ³ , CAI Shan ³ , TAN Xiaoyu ³ , YANG Qingqing ¹ , WU Shanshan ⁴ , CHEN Yahong ⁵ ,  SUN Feng ¹

1. Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, P.R.China;
2. Primary Care Unit, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridgeshire CB1 8RN, UK;
3. Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, P.R.China;
4. National Clinical Research Center of Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, P.R.China;
5. Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing 100191, P.R.China;

Corresponding author：

SUN Feng, Email: sunfeng@bjmu.edu.cn

Keywords：

SARS-CoV-2; β-coronaviruses; Treatment; Efficacy; Systematic review; Meta-analysis

DOI：

10.7507/1672-2531.202105133

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the efficacy of treatments for β-coronaviruses.Methods PubMed, EMbase, Web of Science, The Cochrane Library, SinoMed, CNKI and WanFang Data databases were electronically searched to collect randomized controlled trials (RCTs) and non-randomized controlled trials (non-RCTs) of treatments for β-coronaviruses from inception to June 17^th, 2020. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Meta-analysis was then performed using Stata 14.0 software.Results A total of 109 studies invoving 23 210 patients were included. The results of the systematic review showed that compared with standard of care, corticosteroids could reduce mortality and increase cure rate for COVID-19. However, chloroquine could decrease cure rate. In severe acute respiratory syndrome (SARS) patients, corticosteroids could decrease the cure rate. In Middle East respiratory syndrome (MERS) patients, ribavirin/interferon/both drugs showed higher mortality.Conclusions The currently limited evidence shows that corticosteroids may be effective to COVID-19 patients while having limited effects on SARS patients. Hydroxychloroquine or chloroquine may have negative effects on COVID-19 patients. Ribavirin/interferon may be harmful to MERS patients. Due to limited quality and quantity of the included studies, more high quality studies are needed to verify the above conclusions.

Citation： ZENG Xueyang, ZHOU Qingxin, ZHANG Jingxue, YANG Zhirong, CAI Xianming, CAI Shan, TAN Xiaoyu, YANG Qingqing, WU Shanshan, CHEN Yahong, SUN Feng. Efficacy of treatments for β-coronaviruses associated respiratory diseases: a systematic review. Chinese Journal of Evidence-Based Medicine, 2021, 21(9): 1055-1066. doi: 10.7507/1672-2531.202105133 Copy

1.	Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol, 2020, 92(4): 441-447.
2.	Gorbalenya AE, Baker SC, Baric RS, et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses - a statement of the coronavirus study group. BioRxiv, 2020: 2020-2022.
3.	World Health Organization. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. Available at: https://www.who.int/publications/m/item/summary-of-probable-sars-cases-with-onset-of-illness-from-1-november-2002-to-31-july-2003.
4.	International Committee on Taxonomy of Viruses. ICTV master species list 2018b. v2. Available at: https://talk.ictvonline.org/files/master-species-lists/m/msl/8266.
5.	Zhu Y, Li C, Chen L, et al. A novel human coronavirus OC43 genotype detected in mainland China. Emerg Microbes Infect, 2018, 7(1): 173.
6.	World Health Organization. Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
7.	COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. American: National Institutes of Health. Available at: https://www.covid19treatmentguidelines.nih.gov/.
8.	Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious diseases society of america guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis, 2020: ciaa478.
9.	Alhazzani W, Møller MH, Arabi YM, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Crit Care Med, 2020, 48(6): e440-e469.
10.	Rochwerg B, Agarwal A, Zeng L, et al. Remdesivir for severe covid-19: a clinical practice guideline. BMJ, 2020, 370: m2924.
11.	刘素彦, 王连嵋, 赵雍, 等. 《新型冠状病毒肺炎诊疗方案》推荐的中药注射剂治疗呼吸系统感染性疾病的研究进展. 中国实验方剂学杂志, 2020, 26(12): 1-13.
12.	Knobloch K, Yoon U, Vogt PM. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. J Craniomaxillofac Surg, 2011, 39(2): 91-92.
13.	国家卫生健康委员会, 国家中医药管理局. 新型冠状病毒肺炎诊疗方案(试行第八版). 中国病毒病杂志, 2020, 10: 321-328.
14.	World Health Organization. Clinical management of COVID-19. Living guidance. Available at: https://www.who.int/publications/i/item/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected.
15.	Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ, 2011, 343: d5928.
16.	Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ, 2016, 355: i4919.
17.	Agresti A. On logit confidence intervals for the odds ratio with small samples. Biometrics, 1999, 55(2): 597-602.
18.	Anscombe FJ. On estimating binomial response relations. Biometrika, 1956, 43(3-4): 461-464.
19.	Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med, 2020, 383(19): 1813-1826.
20.	Cao Y, Wei J, Zou L, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol, 2020, 146(1): 137-146.
21.	Davoudi-Monfared E, Rahmani H, Khalili H, et al. A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19. Antimicrob Agents Chemother, 2020, 64(9): e01061-1020.
22.	Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med, 2020, 383(19): 1827-1837.
23.	Horby P, Lim WS, Emberson J, et al. Effect of dexamethasone in hospitalized patients with COVID-19 - preliminary report. MedRxiv, 2020: 2020-2026.
24.	Hu K, Guan WJ, Bi Y, et al. Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial. Phytomedicine, 2021, 85: 153242.
25.	Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA, 2020, 324(5): 460-470.
26.	傅晓霞, 林路平, 谭行华. 中西医结合治疗新型冠状病毒肺炎 37 例临床研究. 中药新药与临床药理, 2020, 31(5): 600-604.
27.	李亚冬, 张文静. 新冠肺炎中西医治疗方案临床效果评价. 光明中医, 2020, 35(9): 1273-1275.
28.	余平, 李叶子, 万少兵, 等. 连花清瘟颗粒联合阿比多尔治疗轻度新型冠状病毒肺炎的疗效观察. 中国药学杂志, 2020, 55(12): 1042-1045.
29.	张传涛, 杨洋, 由凤鸣, 等. 从“疫毒夹湿”论治新型冠状病毒肺炎(COVID-19)的临床研究. 中药药理与临床, 2020, 36(2): 43-46.
30.	张又莉, 雷亮, 徐勇, 等. 金银花口服液治疗新型冠状病毒肺炎80例临床疗效分析. 中国药业, 2020, 29(9): 23-26.
31.	郑子洲, 白志刚, 李常杰, 等. 中医辨证治疗新型冠状病毒肺炎效果观察. 交通医学, 2020, 34(2): 117-118.
32.	周外民, 赵富明, 李榜龙, 等. 甘草酸二胺在普通型新型冠状病毒肺炎患者治疗中的临床价值. 病毒学报, 2020, 36(2): 160-164.
33.	Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med, 2020, 382(19): 1787-1799.
34.	Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, 2020, 395(10236): 1569-1578.
35.	Li Y, Xie Z, Lin W, et al. Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial. Med (NY), 2020, 1(1): 105-113.
36.	Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet, 2020, 395(10238): 1695-1704.
37.	Chen C, Zhang Y, Huang J, et al. Favipiravir versus Arbidol for COVID-19: a randomized clinical trial. MedRxiv, 2020: 2020-2023.
38.	Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ, 2020, 369: m1849.
39.	陈军, 刘丹萍, 刘莉, 等. 硫酸羟氯喹治疗 2019 冠状病毒病(COVID-19)普通型患者的初步研究. 浙江大学学报(医学版), 2020, 49: 215-219.
40.	Borba MGS, Val FFA, Sampaio VS, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open, 2020, 3(4): e208857.
41.	Zhong M, Sun A, Xiao T, et al. A randomized, single-blind, group sequential, active-controlled study to evaluate the clinical efficacy and safety of α-Lipoic acid for critically ill patients with coronavirus disease 2019(COVID-19). MedRxiv, 2020: 2020-2024.
42.	Zheng F, Zhou Y, Zhou Z, et al. A novel protein drug, novaferon, as the potential antiviral drug for COVID-19. MedRxiv, 2020: 2020-2024.
43.	Lou Y, Liu L, Yao H, et al. Clinical outcomes and plasma concentrations of baloxavir marboxil and favipiravir in COVID-19 patients: an exploratory randomized, controlled trial. Eur J Pharm Sci, 2021, 157: 105631.
44.	Zhang Z, Wang S, Tu X, et al. A comparative study on the time to achieve negative nucleic acid testing and hospital stays between danoprevir and lopinavir/ritonavir in the treatment of patients with COVID-19. J Med Virol, 2020, 92(11): 2631-2636.
45.	Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA, 2020, 323(24): 2493-2502.
46.	Panagopoulos P, Petrakis V, Panopoulou M, et al. Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection. J Chemother, 2021, 33(3): 193-197.
47.	Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol, 2020, 5(9): 1036-1041.
48.	Magagnoli J, Narendran S, Pereira F, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. MedRxiv, 2020: 2020-2024.
49.	Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol, 2020, 2(6): e325-e331.
50.	Campochiaro C, Della-Torre E, Cavalli G, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med, 2020, 76: 43-49.
51.	Capra R, De Rossi N, Mattioli F, et al. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur J Intern Med, 2020, 76: 31-35.
52.	Mallat J, Hamed F, Balkis M, et al. Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease. Medicine (Baltimore), 2020, 99(52): e23720.
53.	Lian N, Xie H, Lin S, et al. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. Clin Microbiol Infect, 2020, 26(7): 917-921.
54.	Huang M, Li M, Xiao F, et al. Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19. MedRxiv, 2020: 2020-2024.
55.	Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med, 2020, 382(25): 2411-2418.
56.	Yuan M, Xu X, Xia D, et al. Effects of corticosteroid treatment for non-severe COVID-19 pneumonia: a propensity score-based analysis. Shock, 2020, 54(5): 638-643.
57.	程德忠, 王文菊, 李毅, 等. 51 例新型冠状病毒肺炎患者应用中药连花清瘟疗效分析: 多中心回顾性研究. 天津中医药, 2020, 37: 509-516.
58.	李旷宇, 安薇, 夏飞, 等. 清肺排毒汤加减方联合抗病毒药物治疗新型冠状病毒肺炎的回顾性研究. 中草药, 2020, 51: 2046-2049.
59.	李威, 柳德兵. 甲泼尼龙琥珀酸钠治疗新型冠状病毒肺炎的有效窗口期. 武汉大学学报(医学版), 2020, 41(6): 870-874.
60.	李新刚, 徐艳利, 王琳, 等. 糖皮质激素在新型冠状病毒肺炎重型患者治疗中的临床研究. 首都医科大学学报, 2020, 41(3): 345-349.
61.	柳丽丽, 冯毅, 孙东, 等. 阿比多尔联合连花清瘟胶囊治疗新型冠状病毒肺炎的临床观察. 广东医学, 2020, 41(12): 1207-1210.
62.	秦娅蓝, 宋玉燕, 周璐, 等. 热毒宁联合甲泼尼龙治疗重症新型冠状病毒肺炎临床疗效评价. 中国药业, 2020, 29(9): 19-22.
63.	时佳, 杨宗国, 叶晨, 等. 中西医结合治上海地区 49 例非危重型新型冠状病毒肺炎临床疗效观察. 上海中医药杂志, 2020, 54(4): 30-35.
64.	魏茹楠, 蒋贤高, 马春莲, 等. 浙江省新型冠状病毒肺炎患者早期阿比多尔+洛匹那韦/利托那韦+重组干扰素 α-2b 联合抗病毒治疗的多中心、前瞻性研究. 中华临床感染病杂志, 2020, 13(1): 9-15.
65.	温春燕, 谢志伟, 李粤平, 等. 洛匹那韦/利托那韦及阿比多尔治疗新型冠状病毒肺炎的疗效和安全性观察. 中华内科杂志, 2020, 59(8): 605-609.
66.	Xu P, Huang J, Fan Z, et al. Arbidol/IFN-α2b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study. Microbes Infect, 2020, 22(4-5): 200-205.
67.	杨倩, 孙勤国, 江波, 等. 中西医结合治疗新型冠状病毒肺炎重症患者的回顾性临床研究. 中草药, 2020, 51(8): 2050-2054.
68.	杨勇, 吴慕禹, 苗丽霞, 等. 高压氧辅助治疗新型冠状病毒肺炎的介入时机及其临床疗效. 中国医学物理学杂志, 2020, 37(5): 641-643.
69.	余爱荣, 范星, 赵燕, 等. 洛匹那韦/利托那韦联合其他抗病毒药治疗新型冠状病毒肺炎的疗效与安全性. 医药导报, 2020, 39: 628-632.
70.	Carlucci PM, Ahuja T, Petrilli C, et al. Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients. MedRxiv, 2020: 2020-2025.
71.	Quartuccio L, Sonaglia A, McGonagle D, et al. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care. J Clin Virol, 2020, 129: 104444.
72.	Zha L, Li S, Pan L, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust, 2020, 212(9): 416-420.
73.	Yu B, Li C, Chen P, et al. Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19. MedRxiv, 2020: 2020-2024.
74.	Deng L, Li C, Zeng Q, et al. Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: a retrospective cohort study. J Infect, 2020, 81(1): e1-e5.
75.	薛平, 柳湘洁, 雷超, 等. 老年普通型新型冠状病毒肺炎治疗中短期小剂量糖皮质激素应用观察. 山东医药, 2020, 60(15): 1-5.
76.	Colaneri M, Bogliolo L, Valsecchi P, et al. Tocilizumab for treatment of severe covid-19 patients: preliminary results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms, 2020, 8(5): 695.
77.	Lan X, Shao C, Zeng X, et al. Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: A pilot retrospective study. Int J Clin Pharmacol Ther, 2021, 59(5): 378-385.
78.	夏文广, 安长青, 郑婵娟, 等. 中西医结合治疗新型冠状病毒肺炎 34 例临床研究. 中医杂志, 2020, 61: 375-382.
79.	瞿香坤, 郝树立, 马景贺, 等. 疏风解毒胶囊联合阿比多尔治疗新型冠状病毒肺炎的回顾性研究. 中草药, 2020, 51(5): 1167-1170.
80.	陈军, 凌云, 席秀红, 等. 洛匹那韦利托那韦和阿比多尔用于治疗新型冠状病毒肺炎的有效性研究. 中华传染病杂志, 2020, 38: 86-89.
81.	Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing), 2020, 6(10): 1192-1198.
82.	Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents, 2020, 56(1): 105949.
83.	刘凡. 中西医结合治疗新型冠状病毒肺炎 42 例疗效观察. 中国管理科学研究院商学院管理创新成果汇编(一). 北京: 中国管理科学研究院商学院, 2020: 7.
84.	Fadel R, Morrison AR, Vahia A, et al. Early short-course corticosteroids in hospitalized patients with COVID-19. Clin Infect Dis, 2020, 71(16): 2114-2120.
85.	肖琦, 蒋茵婕, 吴思思, 等. 中药疏风解毒胶囊联合阿比多尔治疗轻症新型冠状病毒肺炎的价值分析. 中国中医急症, 2020, 29: 756-758.
86.	王融冰, 刘军民, 江宇泳, 等. 中西医结合治疗 SARS 疗效初步分析. 中国中西医结合杂志, 2003, 23(7): 492-493.
87.	Zhao Z, Zhang F, Xu M, et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol, 2003, 52(Pt 8): 715-720.
88.	张立山, 武维屏, 侯一军, 等. 中西医结合治疗传染性非典型肺炎 30 例临床观察. 中医杂志, 2004, 45(9): 675-677.
89.	张允岭, 张晓梅, 金耀文, 等. 中西医结合治疗 65 例非典型肺炎(SARS)的临床研究. 北京中医药大学学报, 2003, 26(6): 60-64.
90.	赵春惠, 李秀惠, 张可, 等. 77 例 SARS 患者中西医结合治疗随机对照研究. 中国中西医结合急救杂志, 2003, 10(4): 197-200.
91.	黄小波, 李宗信, 李斌, 等. 中西医结合治疗 SARS 的临床疗效观察. 中国中医药信息杂志, 2004, 11(2): 144-145.
92.	李志军, 李庆, 鲍凤和, 等. 中西医结合治疗 SARS 临床研究. 杭州: 全国 SARS 防治学术交流会, 2003.
93.	王融冰, 刘军民, 吴云忠, 等. 中西医结合治疗 SARS 疗效分析. 北京: 中医药防治 SARS 学术研讨会, 2003.
94.	张汉丰, 马国强, 郝富, 等. 蒙药清热八味散(额日赫木-8)对 SARS 的临床研究. 内蒙古医学杂志, 2004, 36(10): 732-734.
95.	李海, 卢诚震, 唐克诚, 等. 柴胡滴丸联合藿香正气滴丸治疗 SARS 的临床观察. 中国中西医结合杂志, 2004, 24(4): 321-324.
96.	任爱民, 张淑文, 王宝恩, 等. 中西医结合治疗 SARS 的临床研究. 杭州: 全国 SARS 防治学术交流会, 2003.
97.	李宗信, 黄小波, 李斌, 等. 中西医结合治疗传染性非典型肺炎 122 例临床研究. 中医杂志, 2004, 45(7): 510-511.
98.	Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients. J Clin Virol, 2004, 31(4): 304-309.
99.	王融冰, 刘军民, 江宇泳, 等. 中医药为主治疗 SARS11 例. 北京中医, 2003, 22(3): 8-9.
100.	张纾难. 中西医结合治疗 SARS 所致肺纤维化疗效总结及其临床特点的分析. 中国全科医学, 2003, 6(7): 576-577.
101.	黄小波, 李宗信, 李斌, 等. 中西医结合治疗老年 SARS 患者的临床研究. 中国老年学杂志, 2004, 24(3): 223-225.
102.	Li S, Wang R, Zhang Y, et al. Symptom combinations associated with outcome and therapeutic effects in a cohort of cases with SARS. Am J Chin Med, 2006, 34(6): 937-947.
103.	张晓梅, 张允岭, 杨祖福, 等. 非典 1, 2, 3 号系列方药治疗 SARS 的临床疗效观察. 中国医药学报, 2003, 18(6): 323-325.
104.	夏祖昌, 张重刚, 徐立然, 等. 中西医结合治疗 SARS 证治规律的临床研究. 中华中医药杂志, 2005, 20(4): 243-244.
105.	康静, 陈恒雯, 刘仲云. 中西医结合治疗传染性非典型肺炎 43 例临床观察. 山西中医, 2003, 19(4): 34-35.
106.	Soo YO, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect, 2004, 10(7): 676-678.
107.	Muller MP, Dresser L, Raboud J, et al. Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome. Pharmacotherapy, 2007, 27(4): 494-503.
108.	李平, 刘保延, 翁维良, 等. 中西医结合治疗对 SARS 肺部炎症的影响研究. 北京中医药大学学报, 2005, 28(4): 55-57.
109.	Leong HN, Ang B, Earnest A, et al. Investigational use of ribavirin in the treatment of severe acute respiratory syndrome, Singapore, 2003. Trop Med Int Health, 2004, 9(8): 923-927.
110.	付琦, 李志刚, 贾宝辉, 等. 中西药联合治疗 SARS 253 例疗效分析. 中国中药杂志, 2003, 28(12): 1203-1206.
111.	Ho JC, Ooi GC, Mok TY, et al. High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. Am J Respir Crit Care Med, 2003, 168(12): 1449-1456.
112.	王萍, 李明毅, 史玉亮, 等. 不同严重急性呼吸综合征疗法的疗效评价. 山西医药杂志, 2005, 34(4): 270-272.
113.	张燕萍, 苗青, 黄尧洲, 等. 中西医结合治疗 SARS 临床疗效评价研究. 北京: 华北五省市区及广东省中西医结合防治 SARS 学术会议, 2003.
114.	李秀惠, 胡建华, 张可, 等. 中西医结合治疗 51 例重症 SARS 临床疗效观察. 中华急诊医学杂志, 2004, 13(1): 18-19.
115.	贾卫东. 糖皮质激素在 SARS 治疗中应用的回顾性研究. 广州: 中山大学, 2006.
116.	李秀惠, 张可, 胡建华, 等. 中西医结合治疗 SARS 的临床疗效观察. 中国中西医结合杂志, 2003, 23(7): 489-491.
117.	李秀惠, 张可, 胡建华, 等. 中西医结合治疗严重急性呼吸综合征(SARS)临床疗效观察. 中国医药学报, 2003, 18(6): 326-328.
118.	孙中吉, 李玉明, 吉金利, 等. 26 例 SARS 患者的中西医结合治疗效果观察. 中国中西医结合急救杂志, 2003, 10(4): 217-219.
119.	李楠, 马靖, 聂立功, 等. 肾上腺糖皮质激素治疗 SARS 的回顾性分析. 北京大学学报(医学版), 2003, 35(z1): 16-18.
120.	Loutfy MR, Blatt LM, Siminovitch KA, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA, 2003, 290(24): 3222-3228.
121.	张瑞麟, 焦强, 王保国, 等. 中西医结合治疗 49 例 SARS 临床对照研究. 中国中西医结合杂志, 2003, 23(9): 654-657.
122.	白达富, 格勒, 陶布其, 等. 蒙西医结合治疗 SARS 30 例临床观察. 中国民族医药杂志, 2003, 9(4): 12-12.
123.	刘保延, 何丽云, 梁志伟, 等. 中药参与对 SARS 治疗中肾上腺糖皮质激素用量的影响. 中国中药杂志, 2005, 30(23): 1874-1877.
124.	仝小林, 李平, 刘鹏, 等. 中西医结合治疗 SARS 237 例疗效分析. 北京: 中医药防治 SARS 学术研讨会, 2003.
125.	李宁, 翟晓辉, 高黎, 等. 中药乾坤宁治疗传染性非典型肺炎的临床研究. 中华中西医杂志, 2003, 4(14): 2090-2093.
126.	Shalhoub S, Farahat F, Al-Jiffri A, et al. IFN-α2a or IFN-β1a in combination with ribavirin to treat middle east respiratory syndrome coronavirus pneumonia: a retrospective study. J Antimicrob Chemother, 2015, 70(7): 2129-2132.
127.	Arabi YM, Shalhoub S, Mandourah Y, et al. Ribavirin and interferon therapy for critically ill patients with middle east respiratory syndrome: a multicenter observational study. Clin Infect Dis, 2020, 70(9): 1837-1844.
128.	Yang Z, Liu J, Zhou Y, et al. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. J Infect, 2020, 81(1): e13-e20.13-20.
129.	Ye Z, Wang Y, Colunga-Lozano LE, et al. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis. CMAJ, 2020, 192(27): E756-E767.
130.	Siemieniuk RA, Bartoszko JJ, Ge L, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ, 2020, 370: m2980.
131.	Montón C, Ewig S, Torres A, et al. Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. Eur Respir J, 1999, 14(1): 218-220.
132.	Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res, 2020, 30(3): 269-271.
133.	Eze P, Mezue KN, Nduka CU, et al. Efficacy and safety of chloroquine and hydroxychloroquine for treatment of COVID-19 patients-a systematic review and meta-analysis of randomized controlled trials. Am J Cardiovasc Dis, 2021, 11(1): 93-107.
134.	Diaz-Arocutipa C, Brañez-Condorena A, Hernandez AV. QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis. Pharmacoepidemiol Drug Saf, 2021, 30(6): 694-706.
135.	Ebina-Shibuya R, Namkoong H, Horita N, et al. Hydroxychloroquine and chloroquine for treatment of coronavirus disease 19 (COVID-19): a systematic review and meta-analysis of randomized and non-randomized controlled trials. J Thorac Dis, 2021, 13(1): 202-212.
136.	Takla M, Jeevaratnam K. Chloroquine, hydroxychloroquine, and COVID-19: Systematic review and narrative synthesis of efficacy and safety. Saudi Pharm J, 2020, 28(12): 1760-1776.
137.	Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med, 2006, 3(9): e343.
138.	Atlanta Centers for Disease Control and Prevention. Severe acute respiratory syndrome (SARS). Available at: https://www.cdc.gov/sars/.
139.	Tsang KW, Ho PL, Ooi GC, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med, 2003, 348(20): 1977-1985.
140.	Ren LL, Wang YM, Wu ZQ, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J (Engl), 2020, 133(9): 1015-1024.
141.	Liu M, Gao Y, Yuan Y, et al. Efficacy and safety of integrated traditional chinese and western medicine for corona virus disease 2019 (COVID-19): a systematic review and meta-analysis. Pharmacol Res, 2020, 158: 104896.
142.	Xiong X, Wang P, Su K, et al. Chinese herbal medicine for coronavirus disease 2019: A systematic review and meta-analysis. Pharmacol Res, 2020, 160: 105056.
143.	Sun CY, Sun YL, Li XM. The role of Chinese medicine in COVID-19 pneumonia: A systematic review and meta-analysis. Am J Emerg Med, 2020, 38(10): 2153-2159.
144.	国家卫生健康委办公厅. 新型冠状病毒感染的肺炎诊疗方案(试行第四版). Available at: http://www.nhc.gov.cn/yzygj/s7653p/202001/4294563ed35b43209b31739bd0785e67/files/7a9309111267475a99d4306962c8bf78.pdf.
145.	Luo H, Tang QL, Shang YX, et al. Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs. Chin J Integr Med, 2020, 26(4): 243-250.
146.	Huang CF, Lin SS, Liao PH, et al. The immunopharmaceutical effects and mechanisms of herb medicine. Cell Mol Immunol, 2008, 5(1): 23-31.
147.	Du CY, Zheng KY, Bi CW, et al. Yu Ping Feng San, an ancient Chinese herbal decoction, induces gene expression of anti-viral proteins and inhibits neuraminidase activity. Phytother Res, 2015, 29(5): 656-661.
148.	史洋, 王小平, 白吉庆, 等. 连翘抗菌,抗病毒的药理作用研究. 中国现代中药, 2013, 15(11): 950-953.

1. Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol, 2020, 92(4): 441-447.
2. Gorbalenya AE, Baker SC, Baric RS, et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses - a statement of the coronavirus study group. BioRxiv, 2020: 2020-2022.
3. World Health Organization. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. Available at: https://www.who.int/publications/m/item/summary-of-probable-sars-cases-with-onset-of-illness-from-1-november-2002-to-31-july-2003.
4. International Committee on Taxonomy of Viruses. ICTV master species list 2018b. v2. Available at: https://talk.ictvonline.org/files/master-species-lists/m/msl/8266.
5. Zhu Y, Li C, Chen L, et al. A novel human coronavirus OC43 genotype detected in mainland China. Emerg Microbes Infect, 2018, 7(1): 173.
6. World Health Organization. Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
7. COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. American: National Institutes of Health. Available at: https://www.covid19treatmentguidelines.nih.gov/.
8. Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious diseases society of america guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis, 2020: ciaa478.
9. Alhazzani W, Møller MH, Arabi YM, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Crit Care Med, 2020, 48(6): e440-e469.
10. Rochwerg B, Agarwal A, Zeng L, et al. Remdesivir for severe covid-19: a clinical practice guideline. BMJ, 2020, 370: m2924.
11. 刘素彦, 王连嵋, 赵雍, 等. 《新型冠状病毒肺炎诊疗方案》推荐的中药注射剂治疗呼吸系统感染性疾病的研究进展. 中国实验方剂学杂志, 2020, 26(12): 1-13.
12. Knobloch K, Yoon U, Vogt PM. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. J Craniomaxillofac Surg, 2011, 39(2): 91-92.
13. 国家卫生健康委员会, 国家中医药管理局. 新型冠状病毒肺炎诊疗方案(试行第八版). 中国病毒病杂志, 2020, 10: 321-328.
14. World Health Organization. Clinical management of COVID-19. Living guidance. Available at: https://www.who.int/publications/i/item/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected.
15. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ, 2011, 343: d5928.
16. Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ, 2016, 355: i4919.
17. Agresti A. On logit confidence intervals for the odds ratio with small samples. Biometrics, 1999, 55(2): 597-602.
18. Anscombe FJ. On estimating binomial response relations. Biometrika, 1956, 43(3-4): 461-464.
19. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med, 2020, 383(19): 1813-1826.
20. Cao Y, Wei J, Zou L, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol, 2020, 146(1): 137-146.
21. Davoudi-Monfared E, Rahmani H, Khalili H, et al. A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19. Antimicrob Agents Chemother, 2020, 64(9): e01061-1020.
22. Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med, 2020, 383(19): 1827-1837.
23. Horby P, Lim WS, Emberson J, et al. Effect of dexamethasone in hospitalized patients with COVID-19 - preliminary report. MedRxiv, 2020: 2020-2026.
24. Hu K, Guan WJ, Bi Y, et al. Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial. Phytomedicine, 2021, 85: 153242.
25. Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA, 2020, 324(5): 460-470.
26. 傅晓霞, 林路平, 谭行华. 中西医结合治疗新型冠状病毒肺炎 37 例临床研究. 中药新药与临床药理, 2020, 31(5): 600-604.
27. 李亚冬, 张文静. 新冠肺炎中西医治疗方案临床效果评价. 光明中医, 2020, 35(9): 1273-1275.
28. 余平, 李叶子, 万少兵, 等. 连花清瘟颗粒联合阿比多尔治疗轻度新型冠状病毒肺炎的疗效观察. 中国药学杂志, 2020, 55(12): 1042-1045.
29. 张传涛, 杨洋, 由凤鸣, 等. 从“疫毒夹湿”论治新型冠状病毒肺炎(COVID-19)的临床研究. 中药药理与临床, 2020, 36(2): 43-46.
30. 张又莉, 雷亮, 徐勇, 等. 金银花口服液治疗新型冠状病毒肺炎80例临床疗效分析. 中国药业, 2020, 29(9): 23-26.
31. 郑子洲, 白志刚, 李常杰, 等. 中医辨证治疗新型冠状病毒肺炎效果观察. 交通医学, 2020, 34(2): 117-118.
32. 周外民, 赵富明, 李榜龙, 等. 甘草酸二胺在普通型新型冠状病毒肺炎患者治疗中的临床价值. 病毒学报, 2020, 36(2): 160-164.
33. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med, 2020, 382(19): 1787-1799.
34. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, 2020, 395(10236): 1569-1578.
35. Li Y, Xie Z, Lin W, et al. Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial. Med (NY), 2020, 1(1): 105-113.
36. Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet, 2020, 395(10238): 1695-1704.
37. Chen C, Zhang Y, Huang J, et al. Favipiravir versus Arbidol for COVID-19: a randomized clinical trial. MedRxiv, 2020: 2020-2023.
38. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ, 2020, 369: m1849.
39. 陈军, 刘丹萍, 刘莉, 等. 硫酸羟氯喹治疗 2019 冠状病毒病(COVID-19)普通型患者的初步研究. 浙江大学学报(医学版), 2020, 49: 215-219.
40. Borba MGS, Val FFA, Sampaio VS, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open, 2020, 3(4): e208857.
41. Zhong M, Sun A, Xiao T, et al. A randomized, single-blind, group sequential, active-controlled study to evaluate the clinical efficacy and safety of α-Lipoic acid for critically ill patients with coronavirus disease 2019(COVID-19). MedRxiv, 2020: 2020-2024.
42. Zheng F, Zhou Y, Zhou Z, et al. A novel protein drug, novaferon, as the potential antiviral drug for COVID-19. MedRxiv, 2020: 2020-2024.
43. Lou Y, Liu L, Yao H, et al. Clinical outcomes and plasma concentrations of baloxavir marboxil and favipiravir in COVID-19 patients: an exploratory randomized, controlled trial. Eur J Pharm Sci, 2021, 157: 105631.
44. Zhang Z, Wang S, Tu X, et al. A comparative study on the time to achieve negative nucleic acid testing and hospital stays between danoprevir and lopinavir/ritonavir in the treatment of patients with COVID-19. J Med Virol, 2020, 92(11): 2631-2636.
45. Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA, 2020, 323(24): 2493-2502.
46. Panagopoulos P, Petrakis V, Panopoulou M, et al. Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection. J Chemother, 2021, 33(3): 193-197.
47. Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol, 2020, 5(9): 1036-1041.
48. Magagnoli J, Narendran S, Pereira F, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. MedRxiv, 2020: 2020-2024.
49. Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol, 2020, 2(6): e325-e331.
50. Campochiaro C, Della-Torre E, Cavalli G, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med, 2020, 76: 43-49.
51. Capra R, De Rossi N, Mattioli F, et al. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur J Intern Med, 2020, 76: 31-35.
52. Mallat J, Hamed F, Balkis M, et al. Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease. Medicine (Baltimore), 2020, 99(52): e23720.
53. Lian N, Xie H, Lin S, et al. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. Clin Microbiol Infect, 2020, 26(7): 917-921.
54. Huang M, Li M, Xiao F, et al. Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19. MedRxiv, 2020: 2020-2024.
55. Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med, 2020, 382(25): 2411-2418.
56. Yuan M, Xu X, Xia D, et al. Effects of corticosteroid treatment for non-severe COVID-19 pneumonia: a propensity score-based analysis. Shock, 2020, 54(5): 638-643.
57. 程德忠, 王文菊, 李毅, 等. 51 例新型冠状病毒肺炎患者应用中药连花清瘟疗效分析: 多中心回顾性研究. 天津中医药, 2020, 37: 509-516.
58. 李旷宇, 安薇, 夏飞, 等. 清肺排毒汤加减方联合抗病毒药物治疗新型冠状病毒肺炎的回顾性研究. 中草药, 2020, 51: 2046-2049.
59. 李威, 柳德兵. 甲泼尼龙琥珀酸钠治疗新型冠状病毒肺炎的有效窗口期. 武汉大学学报(医学版), 2020, 41(6): 870-874.
60. 李新刚, 徐艳利, 王琳, 等. 糖皮质激素在新型冠状病毒肺炎重型患者治疗中的临床研究. 首都医科大学学报, 2020, 41(3): 345-349.
61. 柳丽丽, 冯毅, 孙东, 等. 阿比多尔联合连花清瘟胶囊治疗新型冠状病毒肺炎的临床观察. 广东医学, 2020, 41(12): 1207-1210.
62. 秦娅蓝, 宋玉燕, 周璐, 等. 热毒宁联合甲泼尼龙治疗重症新型冠状病毒肺炎临床疗效评价. 中国药业, 2020, 29(9): 19-22.
63. 时佳, 杨宗国, 叶晨, 等. 中西医结合治上海地区 49 例非危重型新型冠状病毒肺炎临床疗效观察. 上海中医药杂志, 2020, 54(4): 30-35.
64. 魏茹楠, 蒋贤高, 马春莲, 等. 浙江省新型冠状病毒肺炎患者早期阿比多尔+洛匹那韦/利托那韦+重组干扰素 α-2b 联合抗病毒治疗的多中心、前瞻性研究. 中华临床感染病杂志, 2020, 13(1): 9-15.
65. 温春燕, 谢志伟, 李粤平, 等. 洛匹那韦/利托那韦及阿比多尔治疗新型冠状病毒肺炎的疗效和安全性观察. 中华内科杂志, 2020, 59(8): 605-609.
66. Xu P, Huang J, Fan Z, et al. Arbidol/IFN-α2b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study. Microbes Infect, 2020, 22(4-5): 200-205.
67. 杨倩, 孙勤国, 江波, 等. 中西医结合治疗新型冠状病毒肺炎重症患者的回顾性临床研究. 中草药, 2020, 51(8): 2050-2054.
68. 杨勇, 吴慕禹, 苗丽霞, 等. 高压氧辅助治疗新型冠状病毒肺炎的介入时机及其临床疗效. 中国医学物理学杂志, 2020, 37(5): 641-643.
69. 余爱荣, 范星, 赵燕, 等. 洛匹那韦/利托那韦联合其他抗病毒药治疗新型冠状病毒肺炎的疗效与安全性. 医药导报, 2020, 39: 628-632.
70. Carlucci PM, Ahuja T, Petrilli C, et al. Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients. MedRxiv, 2020: 2020-2025.
71. Quartuccio L, Sonaglia A, McGonagle D, et al. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care. J Clin Virol, 2020, 129: 104444.
72. Zha L, Li S, Pan L, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust, 2020, 212(9): 416-420.
73. Yu B, Li C, Chen P, et al. Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19. MedRxiv, 2020: 2020-2024.
74. Deng L, Li C, Zeng Q, et al. Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: a retrospective cohort study. J Infect, 2020, 81(1): e1-e5.
75. 薛平, 柳湘洁, 雷超, 等. 老年普通型新型冠状病毒肺炎治疗中短期小剂量糖皮质激素应用观察. 山东医药, 2020, 60(15): 1-5.
76. Colaneri M, Bogliolo L, Valsecchi P, et al. Tocilizumab for treatment of severe covid-19 patients: preliminary results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms, 2020, 8(5): 695.
77. Lan X, Shao C, Zeng X, et al. Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: A pilot retrospective study. Int J Clin Pharmacol Ther, 2021, 59(5): 378-385.
78. 夏文广, 安长青, 郑婵娟, 等. 中西医结合治疗新型冠状病毒肺炎 34 例临床研究. 中医杂志, 2020, 61: 375-382.
79. 瞿香坤, 郝树立, 马景贺, 等. 疏风解毒胶囊联合阿比多尔治疗新型冠状病毒肺炎的回顾性研究. 中草药, 2020, 51(5): 1167-1170.
80. 陈军, 凌云, 席秀红, 等. 洛匹那韦利托那韦和阿比多尔用于治疗新型冠状病毒肺炎的有效性研究. 中华传染病杂志, 2020, 38: 86-89.
81. Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing), 2020, 6(10): 1192-1198.
82. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents, 2020, 56(1): 105949.
83. 刘凡. 中西医结合治疗新型冠状病毒肺炎 42 例疗效观察. 中国管理科学研究院商学院管理创新成果汇编(一). 北京: 中国管理科学研究院商学院, 2020: 7.
84. Fadel R, Morrison AR, Vahia A, et al. Early short-course corticosteroids in hospitalized patients with COVID-19. Clin Infect Dis, 2020, 71(16): 2114-2120.
85. 肖琦, 蒋茵婕, 吴思思, 等. 中药疏风解毒胶囊联合阿比多尔治疗轻症新型冠状病毒肺炎的价值分析. 中国中医急症, 2020, 29: 756-758.
86. 王融冰, 刘军民, 江宇泳, 等. 中西医结合治疗 SARS 疗效初步分析. 中国中西医结合杂志, 2003, 23(7): 492-493.
87. Zhao Z, Zhang F, Xu M, et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol, 2003, 52(Pt 8): 715-720.
88. 张立山, 武维屏, 侯一军, 等. 中西医结合治疗传染性非典型肺炎 30 例临床观察. 中医杂志, 2004, 45(9): 675-677.
89. 张允岭, 张晓梅, 金耀文, 等. 中西医结合治疗 65 例非典型肺炎(SARS)的临床研究. 北京中医药大学学报, 2003, 26(6): 60-64.
90. 赵春惠, 李秀惠, 张可, 等. 77 例 SARS 患者中西医结合治疗随机对照研究. 中国中西医结合急救杂志, 2003, 10(4): 197-200.
91. 黄小波, 李宗信, 李斌, 等. 中西医结合治疗 SARS 的临床疗效观察. 中国中医药信息杂志, 2004, 11(2): 144-145.
92. 李志军, 李庆, 鲍凤和, 等. 中西医结合治疗 SARS 临床研究. 杭州: 全国 SARS 防治学术交流会, 2003.
93. 王融冰, 刘军民, 吴云忠, 等. 中西医结合治疗 SARS 疗效分析. 北京: 中医药防治 SARS 学术研讨会, 2003.
94. 张汉丰, 马国强, 郝富, 等. 蒙药清热八味散(额日赫木-8)对 SARS 的临床研究. 内蒙古医学杂志, 2004, 36(10): 732-734.
95. 李海, 卢诚震, 唐克诚, 等. 柴胡滴丸联合藿香正气滴丸治疗 SARS 的临床观察. 中国中西医结合杂志, 2004, 24(4): 321-324.
96. 任爱民, 张淑文, 王宝恩, 等. 中西医结合治疗 SARS 的临床研究. 杭州: 全国 SARS 防治学术交流会, 2003.
97. 李宗信, 黄小波, 李斌, 等. 中西医结合治疗传染性非典型肺炎 122 例临床研究. 中医杂志, 2004, 45(7): 510-511.
98. Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients. J Clin Virol, 2004, 31(4): 304-309.
99. 王融冰, 刘军民, 江宇泳, 等. 中医药为主治疗 SARS11 例. 北京中医, 2003, 22(3): 8-9.
100. 张纾难. 中西医结合治疗 SARS 所致肺纤维化疗效总结及其临床特点的分析. 中国全科医学, 2003, 6(7): 576-577.
101. 黄小波, 李宗信, 李斌, 等. 中西医结合治疗老年 SARS 患者的临床研究. 中国老年学杂志, 2004, 24(3): 223-225.
102. Li S, Wang R, Zhang Y, et al. Symptom combinations associated with outcome and therapeutic effects in a cohort of cases with SARS. Am J Chin Med, 2006, 34(6): 937-947.
103. 张晓梅, 张允岭, 杨祖福, 等. 非典 1, 2, 3 号系列方药治疗 SARS 的临床疗效观察. 中国医药学报, 2003, 18(6): 323-325.
104. 夏祖昌, 张重刚, 徐立然, 等. 中西医结合治疗 SARS 证治规律的临床研究. 中华中医药杂志, 2005, 20(4): 243-244.
105. 康静, 陈恒雯, 刘仲云. 中西医结合治疗传染性非典型肺炎 43 例临床观察. 山西中医, 2003, 19(4): 34-35.
106. Soo YO, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect, 2004, 10(7): 676-678.
107. Muller MP, Dresser L, Raboud J, et al. Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome. Pharmacotherapy, 2007, 27(4): 494-503.
108. 李平, 刘保延, 翁维良, 等. 中西医结合治疗对 SARS 肺部炎症的影响研究. 北京中医药大学学报, 2005, 28(4): 55-57.
109. Leong HN, Ang B, Earnest A, et al. Investigational use of ribavirin in the treatment of severe acute respiratory syndrome, Singapore, 2003. Trop Med Int Health, 2004, 9(8): 923-927.
110. 付琦, 李志刚, 贾宝辉, 等. 中西药联合治疗 SARS 253 例疗效分析. 中国中药杂志, 2003, 28(12): 1203-1206.
111. Ho JC, Ooi GC, Mok TY, et al. High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. Am J Respir Crit Care Med, 2003, 168(12): 1449-1456.
112. 王萍, 李明毅, 史玉亮, 等. 不同严重急性呼吸综合征疗法的疗效评价. 山西医药杂志, 2005, 34(4): 270-272.
113. 张燕萍, 苗青, 黄尧洲, 等. 中西医结合治疗 SARS 临床疗效评价研究. 北京: 华北五省市区及广东省中西医结合防治 SARS 学术会议, 2003.
114. 李秀惠, 胡建华, 张可, 等. 中西医结合治疗 51 例重症 SARS 临床疗效观察. 中华急诊医学杂志, 2004, 13(1): 18-19.
115. 贾卫东. 糖皮质激素在 SARS 治疗中应用的回顾性研究. 广州: 中山大学, 2006.
116. 李秀惠, 张可, 胡建华, 等. 中西医结合治疗 SARS 的临床疗效观察. 中国中西医结合杂志, 2003, 23(7): 489-491.
117. 李秀惠, 张可, 胡建华, 等. 中西医结合治疗严重急性呼吸综合征(SARS)临床疗效观察. 中国医药学报, 2003, 18(6): 326-328.
118. 孙中吉, 李玉明, 吉金利, 等. 26 例 SARS 患者的中西医结合治疗效果观察. 中国中西医结合急救杂志, 2003, 10(4): 217-219.
119. 李楠, 马靖, 聂立功, 等. 肾上腺糖皮质激素治疗 SARS 的回顾性分析. 北京大学学报(医学版), 2003, 35(z1): 16-18.
120. Loutfy MR, Blatt LM, Siminovitch KA, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA, 2003, 290(24): 3222-3228.
121. 张瑞麟, 焦强, 王保国, 等. 中西医结合治疗 49 例 SARS 临床对照研究. 中国中西医结合杂志, 2003, 23(9): 654-657.
122. 白达富, 格勒, 陶布其, 等. 蒙西医结合治疗 SARS 30 例临床观察. 中国民族医药杂志, 2003, 9(4): 12-12.
123. 刘保延, 何丽云, 梁志伟, 等. 中药参与对 SARS 治疗中肾上腺糖皮质激素用量的影响. 中国中药杂志, 2005, 30(23): 1874-1877.
124. 仝小林, 李平, 刘鹏, 等. 中西医结合治疗 SARS 237 例疗效分析. 北京: 中医药防治 SARS 学术研讨会, 2003.
125. 李宁, 翟晓辉, 高黎, 等. 中药乾坤宁治疗传染性非典型肺炎的临床研究. 中华中西医杂志, 2003, 4(14): 2090-2093.
126. Shalhoub S, Farahat F, Al-Jiffri A, et al. IFN-α2a or IFN-β1a in combination with ribavirin to treat middle east respiratory syndrome coronavirus pneumonia: a retrospective study. J Antimicrob Chemother, 2015, 70(7): 2129-2132.
127. Arabi YM, Shalhoub S, Mandourah Y, et al. Ribavirin and interferon therapy for critically ill patients with middle east respiratory syndrome: a multicenter observational study. Clin Infect Dis, 2020, 70(9): 1837-1844.
128. Yang Z, Liu J, Zhou Y, et al. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. J Infect, 2020, 81(1): e13-e20.13-20.
129. Ye Z, Wang Y, Colunga-Lozano LE, et al. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis. CMAJ, 2020, 192(27): E756-E767.
130. Siemieniuk RA, Bartoszko JJ, Ge L, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ, 2020, 370: m2980.
131. Montón C, Ewig S, Torres A, et al. Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. Eur Respir J, 1999, 14(1): 218-220.
132. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res, 2020, 30(3): 269-271.
133. Eze P, Mezue KN, Nduka CU, et al. Efficacy and safety of chloroquine and hydroxychloroquine for treatment of COVID-19 patients-a systematic review and meta-analysis of randomized controlled trials. Am J Cardiovasc Dis, 2021, 11(1): 93-107.
134. Diaz-Arocutipa C, Brañez-Condorena A, Hernandez AV. QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis. Pharmacoepidemiol Drug Saf, 2021, 30(6): 694-706.
135. Ebina-Shibuya R, Namkoong H, Horita N, et al. Hydroxychloroquine and chloroquine for treatment of coronavirus disease 19 (COVID-19): a systematic review and meta-analysis of randomized and non-randomized controlled trials. J Thorac Dis, 2021, 13(1): 202-212.
136. Takla M, Jeevaratnam K. Chloroquine, hydroxychloroquine, and COVID-19: Systematic review and narrative synthesis of efficacy and safety. Saudi Pharm J, 2020, 28(12): 1760-1776.
137. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med, 2006, 3(9): e343.
138. Atlanta Centers for Disease Control and Prevention. Severe acute respiratory syndrome (SARS). Available at: https://www.cdc.gov/sars/.
139. Tsang KW, Ho PL, Ooi GC, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med, 2003, 348(20): 1977-1985.
140. Ren LL, Wang YM, Wu ZQ, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J (Engl), 2020, 133(9): 1015-1024.
141. Liu M, Gao Y, Yuan Y, et al. Efficacy and safety of integrated traditional chinese and western medicine for corona virus disease 2019 (COVID-19): a systematic review and meta-analysis. Pharmacol Res, 2020, 158: 104896.
142. Xiong X, Wang P, Su K, et al. Chinese herbal medicine for coronavirus disease 2019: A systematic review and meta-analysis. Pharmacol Res, 2020, 160: 105056.
143. Sun CY, Sun YL, Li XM. The role of Chinese medicine in COVID-19 pneumonia: A systematic review and meta-analysis. Am J Emerg Med, 2020, 38(10): 2153-2159.
144. 国家卫生健康委办公厅. 新型冠状病毒感染的肺炎诊疗方案(试行第四版). Available at: http://www.nhc.gov.cn/yzygj/s7653p/202001/4294563ed35b43209b31739bd0785e67/files/7a9309111267475a99d4306962c8bf78.pdf.
145. Luo H, Tang QL, Shang YX, et al. Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs. Chin J Integr Med, 2020, 26(4): 243-250.
146. Huang CF, Lin SS, Liao PH, et al. The immunopharmaceutical effects and mechanisms of herb medicine. Cell Mol Immunol, 2008, 5(1): 23-31.
147. Du CY, Zheng KY, Bi CW, et al. Yu Ping Feng San, an ancient Chinese herbal decoction, induces gene expression of anti-viral proteins and inhibits neuraminidase activity. Phytother Res, 2015, 29(5): 656-661.
148. 史洋, 王小平, 白吉庆, 等. 连翘抗菌,抗病毒的药理作用研究. 中国现代中药, 2013, 15(11): 950-953.

Chinese Journal of Evidence-Based Medicine

Efficacy of treatments for β-coronaviruses associated respiratory diseases: a systematic review

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content